Advances in the formulation and delivery technology of paclitaxel for injection

doi:10.5246/jcps.2015.08.063

Abstract

Abstract:

Paclitaxel is a promising antineoplastic agent against a variety of human solid tumors, such as ovary, breast, lung, head and neck tumors, and melanoma. Owing to its poor solubility, the first available formulation of paclitaxel (Taxol^®) exists as a non-aqueous concentrate composed of Cremophor EL (polyethoxylated castor oil) and ethanol. It must be diluted to a suitable aqueous solution prior to long time intravenous infusion. Based on the components and usage, Taxol^® has serious adverse effects and is inconvenient for clinical use. To address these problems, the development of a less-toxic, better-tolerated, Cremophor EL-free formulation of paclitaxel has been attempted. In recent years, new drug delivery systems (DDS) including albumin-based nanoparticles, micelles, liposomes, etc. have been investigated. In this review, we present the formulations and delivery technologies of paclitaxel for injection and focus on some of preclinical and clinical experience on the formulations which are already on the market or under clinical stages. Finally, possible nanotechnology advantages, existing challenges and future perspectives of paclitaxel delivery are highlighted.

Key words: Paclitaxel, Taxol®, Preclinical and clinical studies, New drug delivery system

CLC Number:

R943

Supporting:

Jing Sun, Wenbing Dai, Zhe Liang, Zhaoyang Wang, Changsheng Huang, Bing He, Hua Zhang, Xueqing Wang, Qiang Zhang. Advances in the formulation and delivery technology of paclitaxel for injection[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(8): 487-500.

References

[1] Rowinsky, E.K.A.D. N. Eng. J. Med. , 332, 1004-10141995.

[2] Joerger, M. Expert Opin. Drug Metab. Toxicol. 2014, 11, 1-12.

[3] Kim, S.C.; Yoon, H.J.; Lee, J.W.; Yu, J.; Park, E.S.; Chi, S.C. Int. J. Pharm. 2005, 293, 303-310.

[4] Sun, Y.; Zhang, X.; Tang, L. J. Chin. Pharm. Sci. 2015, 24, 104-110.

[5] Lin, Z.; Gao, W.; Hu, H.; Ma, K.; He, B.; Dai, W.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. J. Control. Release. 2014, 174, 161-170.

[6] Wang, Y.; Wang, J.; Meng, M.; Zhang, H.; Zhang, Q. 2010, 19, 214-222.

[7] Elsadek, B.; Kratz, F. J. Control. Release. 2012, 157, 4-28.

[8] Hawkins, M.J.; Soon-Shiong, P.; Desai, N. Adv. Drug Deliv. Rev. 2008, 60, 876-885.

[9] Lluch, A.; Alvarez, I.; Munoz, M.; Segui, M.A.; Tusquets, I.; Garcia-Estevez, L. Crit. Rev. Oncol. Hematol. 2014, 89, 62-72.

[10] Sparreboom, A.; Scripture, C.D.; Trieu, V.; Williams, P.J.; De, T.; Yang, A.; Beals, B.; Figg, W.D.; Hawkins, M.; Desai, N. Clin. Cancer Res. 2005, 11, 4136-4143.

[11] Sparreboom, A.; van Zuylen, L.; Brouwer, E.; Loos, W. J.; de Bruijn, P.; Gelderblom, H.; Pillay, M.; Nooter, K.; Stoter, G.; Verweij, J. Cancer Res. 1999, 59, 1454-1457.

[12] Svenson, S. Wiley Interdiscip Rev. Nanomed Nanobiotechnol. 2014, 6, 125-135.

[13] Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T; Beals, B.; Dykes, D.; Noker, P.; Yao, R.; Labao, E.; Hawkins, M.; Soon-Shiong, P. Clin. Cancer Res. 2006, 12, 1317-1324.

[14] Hawkins, M.J.; Soon-Shiong, P.; Desai, N. Adv. Drug Deliv. Rev. 2008, 60, 876-885.

[15] Nyman, D.W.; Campbell, K.J.; Hersh, E.; Long, K.; Richardson, K.; Trieu, V.; Desai, N.; Hawkins, M.J.; Von Hoff, D.D. J. Clin. Oncol. 2005, 23, 7785-7793.

[16] Ibrahim, N.K.; Samuels, B.; Page, R.; Doval, D.; Patel, K.M.; Rao, S.C.; Nair, M.K.; Bhar, P.; Desai, N.; Hortobagyi, G.N. J. Clin. Oncol. 2005, 23, 6019-6026.

[17] Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. J. Clin. Oncol. 2005, 23, 7794-7803.

[18] Gupta, N.; Hatoum, H.; Dy, G.K. Int. J. Nanomed. 2014, 9, 209-221.

[19] Hirsh, V.; Okamoto, I.; Hon, J.K.; Page, R.D.; Orsini, J.; Sakai, H.; Zhang, H.; Renschler, M.F.; Socinski, M.A. J. Thorac. Oncol. 2014, 9, 83-90.

[20] Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; Harris, M.; Reni, M.; Dowden, S.; Laheru, D.; Bahary, N.; Ramanathan, R.K.; Tabernero, J.; Hidalgo, M.; Goldstein, D.; Van Cutsem, E.; Wei, X.; Iglesias, J.; Renschler, M.F. N. Engl. J. Med. 2013, 369, 1691-1703.

[21] Perez, E.A. Breast Cancer Res. Treat. 2009, 114, 195-201.

[22] Ye, L.; He, J.; Hu, Z.; Dong, Q.; Wang, H.; Fu, F.; Tian, J. Food Chem. Toxicol. 2013, 52, 200-206.

[23] Wang, H.; Cheng, G.; Du, Y.; Ye, L.; Chen, W.; Zhang, L.; Wang, T.; Tian, J.; Fu, F. Mol. Med. Rep. 2013, 7, 947-952.

[24] Yang, A.Z.; Li, J.; Xu, H.J.; Chen, H.Y. Bull. Chin. Cancer. 2006, 15, 862-864.

[25] Ye, L.; He, J.; Hu, Z.; Dong, Q.; Wang, H.; Fu, F.; Tian, J. Food Chem. Toxicol. 2013, 52, 200-206.

[26] Wang, X.; Zhou, J.; Wang, Y.; Zhu, Z.; Lu, Y.; Wei, Y.; Chen, L. Eur. J. Cancer. 2010, 46, 1474-1480.

[27] Wang, X.; Zheng, H.; Zhu, Z.; Wei, Y.; Chen, L. J. Pharm. Sci. 2010, 99, 4746-4752.

[28] Xu, X.; Wang, L.; Xu, H.Q.; Huang, X.E.; Qian, Y.D.; Xiang, J. Asian Pac. J. Cancer Prev. 2013, 14, 2591-2594.

[29] Che, Q.; Zhang, Q.Z.; Liu, J.; Li, L.Q.; Zhao, W.H.; Wang, Y.J.; Zhou, Q.H.; Li, L. Chin. J. Oncol. 2003, 25, 190-192.

[30] Lin, J.G.; Yi, L.C.; Shi, H. Bull. Chin. Cancer. 2008, 17, 326-327.

[31] Zhang, Q.; Huang, X.E.; Gao, L.L. Biomed. Pharmacother. 2009, 63, 603-607.

[32] Koudelka, S.; Turanek, J. J. Control. Release. 2012, 163, 322-334.

[33] Zhang, J.A.; Anyarambhatla, G.; Ma, L.; Ugwu, S.; Xuan, T.; Sardone, T.; Ahmad, I. Eur. J. Pharm. Biopharm. 2005, 59, 177-187.

[34] Fetterly, G.J.; Grasela, T.H.; Sherman, J.W.; Dul, J.L.; Grahn, A.; Lecomte, D.; Fiedler-Kelly, J.; Damjanov, N.; Fishman, M.; Kane, M.P.; Rubin, E.H.; Tan, A.R. Clin. Cancer Res. 2008, 14, 5856-5863.

[35] Slingerland, M.; Guchelaar, H.J.; Rosing, H.; Scheulen, M.E.; van Warmerdam, L.J.; Beijnen, J.H.; Gelderblom, H. Clin. Ther. 2013, 35, 1946-1954.

[36] Abu, L.A.; Ishida, T.; Kiwada, H. Pharm. Res. 2010, 27, 1171-1183.

[37] Krasnici, S.; Werner, A.; Eichhorn, M.E.; Schmitt-Sody, M.; Pahernik, S.A.; Sauer, B.; Schulze, B.; Teifel, M.; Michaelis, U.; Naujoks, K.; Dellian, M. Int. J. Cancer. 2003, 105, 561-567.

[38] Thurston, G.; McLean, J.W.; Rizen, M.; Baluk, P.; Haskell, A.; Murphy, T.J.; Hanahan, D.; McDonald, D. M. J. Clin. Invest. 1998, 101, 1401-1413.

[39] Strieth, S.; Eichhorn, M.E.; Sauer, B.; Schulze, B.; Teifel, M.; Michaelis, U.; Dellian, M. Int. J. Cancer. 2004, 110, 117-124.

[40] Schuch, G. Curr. Opin. Investig. Drugs. 2005, 6, 1259-1265.

[41] Schmitt-Sody, M.; Strieth, S.; Krasnici, S.; Sauer, B.; Schulze, B.; Teifel, M.; Michaelis, U.; Naujoks, K.; Dellian, M. Clin. Cancer Res. 2003, 9, 2335-2341.

[42] Kunstfeld, R.; Wickenhauser, G.; Michaelis, U.; Teifel, M.; Umek, W.; Naujoks, K.; Wolff, K.; Petzelbauer, P. J. Invest. Dermatol. 2003, 120, 476-482.

[43] Bode, C.; Trojan, L.; Weiss, C.; Kraenzlin, B.; Michaelis, U.; Teifel, M.; Alken, P.; Michel, M.S. Oncol. Rep. 2009, 22, 321-326.

[44] Lohr, J.M.; Haas, S.L.; Bechstein, W.O.; Bodoky, G.; Cwiertka, K.; Fischbach, W.; Folsch, U.R.; Jager, D.; Osinsky, D.; Prausova, J.; Schmidt, W.E.; Lutz, M.P. Ann. Oncol. 2012, 23, 1214-1222.

[45] Awada, A.; Bondarenko, I.N.; Bonneterre, J.; Nowara, E.; Ferrero, J.M.; Bakshi, A.V.; Wilke, C.; Piccart, M. Ann. Oncol. 2014, 25, 824-831.

[46] Strieth, S.; Dunau, C.; Michaelis, U.; Jager, L.; Gellrich, D.; Wollenberg, B.; Dellian, M. Head Neck. 2014, 110, 976-984.

[47] Yokoyama, M.; Okano, T.; Sakurai, Y.; Ekimoto, H.; Shibazaki, C.; Kataoka, K. Cancer Res. 1991, 51, 3229-3236.

[48] Zhang, Z.; Mei, L.; Feng, S.S. Expert. Opin. Drug Deliv. 2013, 10, 325-340.

[49] Lee, S.W.; Yun, M.H.; Jeong, S.W.; In, C.H.; Kim, J.Y.; Seo, M.H.; Pai, C.M.; Kim, S.O. J. Control. Release. 2011, 115, 262-271.

[50] Kim, T.Y.; Kim, D.W.; Chung, J.Y.; Shin, S.G.; Kim, S.C.; Heo, D.S.; Kim, N.K.; Bang, Y.J. Clin. Cancer Res. 2004, 10, 3708-3716.

[51] Kim, S.C.; Kim, D.W.; Shim, Y.H.; Bang, J.S.; Oh, H.S.; Wan, K.S.; Seo, M.H. J. Control. Release. 2001, 72, 191-202.

[52] Stirland, D.L.; Nichols, J.W.; Miura, S.; Bae, Y.H. J. Control. Release. 2013, 172, 1045-1064.

[53] Werner, M.E.; Cummings, N.D.; Sethi, M.; Wang, E.C.; Sukumar, R.; Moore, D.T.; Wang, A.Z. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86, 463-468.

[54] Lee, K.S.; Chung, H.C.; Im, S.A.; Park, Y.H.; Kim, C.S.; Kim, S.B.; Rha, S.Y.; Lee, M.Y.; Ro, J. Breast. Cancer Res. Treat. 2008, 108, 241-250.

[55] Hamaguchi, T.; Matsumura, Y.; Suzuki, M.; Shimizu, K.; Goda, R.; Nakamura, I.; Nakatomi, I.; Yokoyama, M.; Kataoka, K.; Kakizoe, T. Br. J. Cancer. 2005, 92, 1240-1246.

[56] Negishi, T.; Koizumi, F.; Uchino, H.; Kuroda, J.; Kawaguchi, T.; Naito, S.; Matsumura, Y. Br. J. Cancer. 2006, 5, 601-606.

[57] Matsumura, Y.; Kataoka, K. Cancer Sci. 2009, , 572-57995.

[58] Hamaguchi, T.; Kato, K.; Yasui, H.; Morizane, C.; Ikeda, M.; Ueno, H.; Muro, K.; Yamada, Y.; Okusaka, T.; Shirao, K.; Shimada, Y.; Nakahama, H.; Matsumura, Y. Br. J. Cancer. 2007, 97, 170-176.

[59] Kato, K.; Chin, K.; Yoshikawa, T.; Yamaguchi, K.; Tsuji, Y.; Esaki, T.; Sakai, K.; Kimura, M.; Hamaguchi, T.; Shimada, Y.; Matsumura, Y.; Ikeda, R. Invest. New Drugs. 2012, 30, 1621-1627.

[60] Vellimana, A.K.; Recinos, V.R.; Hwang, L.; Fowers, K.D.; Li, K.W.; Zhang, Y.; Okonma, S.; Eberhart, C.G.; Brem, H.; Tyler, B.M. J. Neurooncol. 2013, 111, 229-236.

[61] Tyler, B.M.; Hdeib, A.; Caplan, J.; Legnani, F.G.; Fowers, K.D.; Brem, H.; Jallo, G.; Pradilla, G. J. Neurosurg. Spine. 2012, 16, 93-101.

[62] Elstad, N.L.; Fowers, K.D. Adv. Drug Deliv. Rev. 2009, 61, 785-794.

[63] Vukelja, S.J.; Anthony, S.P.; Arseneau, J.C.; Berman, B.S.; Cunningham, C.C.; Nemunaitis, J.J.; Samlowski, W.E.; Fowers, K.D. Anticancer Drugs. 2007, 18, 283-289.

[64] DuVall, G.A.; Tarabar, D.; Seidel, R.H.; Elstad, N.L.; Fowers, K.D. Anticancer Drugs. 2009, 20, 89-95.

[65] Shilo, M.; Reuveni, T.; Motiei, M.; Popovtzer, R. Nanomedicine (Lond). 2012, 7, 257-269.

[66] Jain, R.K.; Stylianopoulos, T. Nat. Rev. Clin. Oncol. 2010, 7, 653-664.

[67] Kleinstreuer, C.; Feng, Y.; Childress, E. World J. Clin. Cases. 2014, 2, 742-756.

[68] Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Mol. Pharm. 2008, 5, 505-515.

[69] Kobayashi, H.; Watanabe, R.; Choyke, P.L. Theranostics. 2013, 4, 81-89.

[70] Maruyama, K. Adv. Drug Deliv. Rev. 2011, 63, 161-169.

[71] Brannon-Peppas, L.; Blanchette, J.O. Adv. Drug Deliv. Rev. 2004, 56, 1649-1659.

[72] Egusquiaguirre, S.P.; Igartua, M.; Hernandez, R.M.; Pedraz, J.L. Clin. Transl. Oncol. 2012, 14, 83-93.

[73] Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. J. Control. Release. 2000, 65, 271-284.

[74] Fang, J.; Nakamura, H.; Maeda, H. Adv. Drug Deliv. Rev. 2011, 63, 136-151.

[75] Acharya, S.; Sahoo, S.K. Adv. Drug Deliv. Rev. 2011, 63, 170-183.

[76] Y Raymond, B. Weiss, R.C.D.P.; Donald, L.; Trump, J.R.B.J. J. Clin. Oncol. 1990, 8, 1263-1268.

[77] Moghimi, S.M.; Bonnemain, B. Adv. Drug Deliv. Rev. 1999, 37, 295-312.

[78] Zhao, J.; Chai, Y.D.; Zhang, J.; Huang, P.F.; Nakashima, K.; Gong, Y.K. Acta Biomater. 2015, 16, 94-102.

[79] Khalid, M.N.; Simard, P.; Hoarau, D.; Dragomir, A.; Leroux, J.C. Pharm. Res. 2006, 23, 752-758.

[80] Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Pharmacol. Rev. 2001, 53, 283-318.

[81] Owens, D.R.; Peppas, N.A. Int. J. Pharm. 2006, 307, 93-102.

[82] Chaudhari, K.R.; Ukawala, M.; Manjappa, A.S.; Kumar, A.; Mundada, P.K.; Mishra, A.K.; Mathur, R.; Monkkonen, J.; Murthy, R.S. Pharm. Res. 2012, 29, 53-68.

[83] Shapira, A.; Livney, Y.D.; Broxterman, H.J.; Assaraf, Y.G. Drug Resist. Updat. 2011, 14, 150-163.

[84] Koziara, J.M.; Whisman, T.R.; Tseng, M.T.; Mumper, R.J. J. Control. Release. 2006, 112, 312-319.

[85] Miyamoto, Y.; Oda, T.; Maeda, H. Cancer Res. 1990, 50, 1571-1575.

[86] Baumann, M.D.; Kang, C.E.; Tator, C.H.; Shoichet, M.S. Biomaterials. 2010, 31, 7631-7639.

[87] Maruyama, K.; Yuda, T.; Okamoto, A.; Kojima, S.; Suginaka, A.; Iwatsuru, M. Biochim. Biophys. Acta. 1992, 1128, 44-49.

[88] Liu, D.; Mori, A.; Huang, L. Biochim. Biophys. Acta. 1992, 1104, 95-101.